= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Sickmann

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Wednesday at 14:30 (Chair: Tim Collier)

Building Standards for Proteomics: A Targeted Mass Spectrometry Approach for Quantification of Cardiovascular Disease Biomarker in Human Blood

Albert Sickmann (Presenter)

Presenter Bio(s): Albert Sickmann is the director of the Leibniz Institute for Analytical Sciences (ISAS e.V.) and head of the department “Bioanalytics“. Furthermore, he is professor at the Ruhr-University Bochum (Faculty of Medicine) and the University of Aberdeen. His research interests are the highly complex signalling and metabolic pathways in cells and cell layers in the human body at different levels by developing and using techniques to measure signalling pathways with spatial and temporal resolution.

Authors: Christin Lorenz, Sebastian Malchow, Christina Looße and Albert Sickmann
Leibniz-Institut für Analytische Wissenschaften – ISAS – e.V.


Platelets are primarily known to be key players in thrombosis and hemostasis. Targeting platelet function and signaling may represent novel therapeutic strategies in prevention of cardiovascular diseases. The absolute quantification of phosphorylation sites in actived platelets can direct the establishment of new diagnostic assays by characterization of samples with clinical relevance, including quantification of platelet receptors and signaling proteins and their regulation via posttranslational modifications in human blood.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: